▲ +161.87% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $18.75, with a high forecast of $23.00 and a low forecast of $17.00. The average price target represents a 161.87% upside from the last price of $7.16.
The current consensus among 4 investment analysts is to buy stock in Verona Pharma. This Buy consensus rating has held steady for over two years.
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.